Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia.

Authors :: Sbrana F
Pino BD
Bigazzi F
Sampietro T
Source :: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis [Clin Investig Arterioscler] 2024 Jan-Feb; Vol. 36 (1), pp. 35-37. Date of Electronic Publication: 2023 Nov 27.
Publication Year :: 2024
Abstract: "The lower, the better" is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.<br /> (Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)

Subjects :: Humans
Female
Aged
Cholesterol, LDL
Ezetimibe therapeutic use
Hyperlipoproteinemia Type II drug therapy
Hypercholesterolemia
Xanthomatosis etiology
Anticholesteremic Agents pharmacology
Anticholesteremic Agents therapeutic use

Language :: English; Spanish; Castilian
ISSN :: 1578-1879
Volume :: 36
Issue :: 1
Database :: MEDLINE
Journal :: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Publication Type :: Academic Journal
Accession number :: 38016879
Full Text :: https://doi.org/10.1016/j.arteri.2023.11.002

Full Text Access

Tools